CARDIOPROGRESS
Foundation for the advancement of cardiology

The Scientific Committee begins accepting abstracts and applications for the scientific program of the XI International Forum of Cardiology and Internal Medicine Dear Colleagues! We invite you to take part in XI International Forum of Cardiology and Internal Medicine. Forum will take place on 22-24 March 2022 in Moscow (online).

Analysis of the activities of the "Cardioprogress" foundation: results of 2021 Dear colleagues! In 2021, a number of significant events took place in cardiology. Due to the continuation of restrictive measures, most scientific events were organized online. This required adaptation and the acquisition of new skills. However, all planned events took place.

FDA Clears Architect Stat High-Sensitivity Troponin Test for MI The US Food and Drug Administration (FDA) has approved the Architect Stat (Abbott Laboratories) high-sensitivity troponin-I assay, which can detect myocardial infarction (MI) faster and more accurately than other troponin tests, according to the company.

World Heart Day 2019 This year on World Heart Day, as part of our mission to ensure heart health equity for all, we want to create a global community of Heart Heroes … people from all walks of life who are acting now to live longer, better, heart-healthy lives by making a promise: for MY HEART, for YOUR HEART, for ALL OUR HEARTS.

ESC 2019: Wrap up in Russian - Live and interactive programme In collaboration with the Russian Society of Cardiology, this programme is designed to present a selection of scientific highlights from ESC Congress and discuss clinical practice implications with experts.

ESC Congress 2019 together with World Congress of Cardiology ESC Congress 2019 together with World Congress of Cardiology Saturday 31 August - Wednesday 4 September 2019 Paris - France

Announcement of the European Congress of Cardiology From August 31 to September 4, 2019, he Congress of the European Society of Cardiology in conjunction with the World Congress of Cardiology - will be held in Paris (France).

Trial Evaluating Sacubitril/Valsartan for HFpEF Misses Primary End Point Full detailed data from PARAGON-HF will be presented at the ESC Congress 2019 in September. Novartis announced topline results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan (Entresto) in heart failure patients with preserved ejection fraction (HFpEF).

ESC Congress 2019 together with World Congress of Cardiology Full detailed data from PARAGON-HF will be presented at the ESC Congress 2019 in September. Novartis announced topline results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan (Entresto) in heart failure patients with preserved ejection fraction (HFpEF).

Certain Social, Behavioral Factors Associated With Diabetes and Hypertension Onset Education and exercise may determine early start of diabetes and hypertension. Select behavioral and social risk factors were correlated with early onset of hypertension and diabetes, a prospective cohort study found. At 3.5 years of follow-up, among the patients without diabetes at baseline, 4% developed diabetes, while 6.4% of the cohort without baseline hypertension developed hypertension, reported Matthew Pantell, MD, MS, of the University of California, San Francisco, and colleagues.